"Nanoformulation" and "Nanoparticles" Again, th
Post# of 22465
Posted On: 11/22/2016 3:00:36 AM
"Nanoformulation" and "Nanoparticles"
Again, this could be far fetched, but as I am reading another article about Nitto Denko's new licensing deal with Bristol-Myers I notice the word "nanoformulation" and "nanoparticles" being mentioned in this article so I can't help but wonder WHAT IF.... I am by no means any type of expert in pharmaceutical deliveries or bio-medicine but I have seen QD technology being used in SLNs and biomedical research when doing my DD on QMC over the last 12-18 months. I very well could be attempting to connect dots that are not to be connected but the wide variety of uses for QDs in the years to come is what attracted me to QMC in the first place. Display's obviously will come first but the tipping point in me buying into QMC pretty heavily was the endless possibilities that QDs can be used for especially in solar and bio-medicine. So obviously this would be something later down the road but if we successfully meet Nitto's needs for the ultra thin polarizer then we will also be there to fulfill it's needs for other fields as well. Can't help but get excited from the news of QD Vision being sold for $70M! GLTA!
Bristol-Myers Squibb Co.'s deal to license worldwide rights to Nitto Denko Corp.'s antifibrotic siRNA therapy gives the pharma one of industry's broadest fibrosis pipelines — and the ability to test multiple combinations.
BMS now owns or has options to acquire fibrosis programs with five mechanisms, none of which reside in the pipelines of major competitors. Gilead Sciences Inc. and Allergan plc each have three clinical fibrosis programs.
Under the Nov. 10 deal, Nitto granted BMS exclusive, worldwide rights to ND-L02-s0201, a vitamin A-coupled lipid nanoformulation of an siRNA against serpin peptidase inhibitor clade H member 1 (SERPINH1; Hsp47). The compound is in a Phase Ib trial to treat advanced fibrosis due to NASH or HCV, with data expected in 2H17.
Nitto will receive $100 million up front and is eligible for undisclosed milestones, plus royalties.
BMS also received an option to license preclinical candidates from Nitto's vitamin A-formulated Hsp47 siRNA pipeline to treat fibrosis in the lungs and other organs.
According to BioCentury's BCIQ database, the upfront payment is one of the 10 largest in a licensing deal for a Phase I candidate since 2009.
Again, this could be far fetched, but as I am reading another article about Nitto Denko's new licensing deal with Bristol-Myers I notice the word "nanoformulation" and "nanoparticles" being mentioned in this article so I can't help but wonder WHAT IF.... I am by no means any type of expert in pharmaceutical deliveries or bio-medicine but I have seen QD technology being used in SLNs and biomedical research when doing my DD on QMC over the last 12-18 months. I very well could be attempting to connect dots that are not to be connected but the wide variety of uses for QDs in the years to come is what attracted me to QMC in the first place. Display's obviously will come first but the tipping point in me buying into QMC pretty heavily was the endless possibilities that QDs can be used for especially in solar and bio-medicine. So obviously this would be something later down the road but if we successfully meet Nitto's needs for the ultra thin polarizer then we will also be there to fulfill it's needs for other fields as well. Can't help but get excited from the news of QD Vision being sold for $70M! GLTA!
Bristol-Myers Squibb Co.'s deal to license worldwide rights to Nitto Denko Corp.'s antifibrotic siRNA therapy gives the pharma one of industry's broadest fibrosis pipelines — and the ability to test multiple combinations.
BMS now owns or has options to acquire fibrosis programs with five mechanisms, none of which reside in the pipelines of major competitors. Gilead Sciences Inc. and Allergan plc each have three clinical fibrosis programs.
Under the Nov. 10 deal, Nitto granted BMS exclusive, worldwide rights to ND-L02-s0201, a vitamin A-coupled lipid nanoformulation of an siRNA against serpin peptidase inhibitor clade H member 1 (SERPINH1; Hsp47). The compound is in a Phase Ib trial to treat advanced fibrosis due to NASH or HCV, with data expected in 2H17.
Nitto will receive $100 million up front and is eligible for undisclosed milestones, plus royalties.
BMS also received an option to license preclinical candidates from Nitto's vitamin A-formulated Hsp47 siRNA pipeline to treat fibrosis in the lungs and other organs.
According to BioCentury's BCIQ database, the upfront payment is one of the 10 largest in a licensing deal for a Phase I candidate since 2009.
(1)
(0)